Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal of Endocrinology · August 6, 2026
Encouraging direction, but not yet definitive.
This cross-sectional case-control study demonstrates that circulating asprosin is significantly elevated in patients with metabolic syndrome across the glycemic spectrum and shows diagnostic discrimination (AUC 0.807–0.863) for dysglycemia. The findings suggest asprosin may serve as a biomarker for cardiometabolic risk, but prospective validation is required before clinical application.
Case-control study. 120 participants stratified into healthy controls, metabolic syndrome without diabetes, metabolic syndrome with prediabetes, and metabolic syndrome with type 2 diabetes mellitus.. Intervention: Measurement of serum asprosin levels and biochemical indices. Compared with: Stratification by glycemic status (healthy controls vs. three metabolic syndrome groups). n = 120.
Serum asprosin levels significantly elevated in all metabolic syndrome cohorts compared to controls (p < 0.001) ROC analysis: AUC = 0.863 for metabolic syndrome with prediabetes, AUC = 0.839 for metabolic syndrome with type 2 diabetes, AUC = 0.807 for isolated metabolic syndrome Asprosin correlated positively with body mass index, waist circumference, fasting glucose, HbA1c, HOMA-IR, and atherogenic lipids
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated prospectively, elevated asprosin could serve as an adjunctive biomarker for cardiometabolic risk stratification and identification of dysglycemia. Current evidence supports hypothesis generation but not yet clinical implementation; additional studies with prospective design and external validation cohorts are needed.
A well-designed case-control study with clear biochemical findings and diagnostic ROC performance, but limited by cross-sectional design, moderate sample size, and lack of prospective validation for predictive utility.
As stated by the source record.
Quoted from the source exactly as published.
If validated prospectively, elevated asprosin could serve as an adjunctive biomarker for cardiometabolic risk stratification and identification of dysglycemia. Current evidence supports hypothesis generation but not yet clinical implementation; additional studies with prospective design and external validation cohorts are needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Metabolic syndrome is a cluster of conditions, including insulin resistance and central obesity, that significantly increase the risk of cardiovascular disease and type 2 diabetes mellitus. Asprosin, a novel fasting-induced adipokine, is implicated in glucose homeostasis and appetite regulation; however, its role across the glycemic continuum in metabolic syndrome remains unclear. This study purposed to evaluate serum asprosin levels in patients with metabolic syndrome stratified by glycemic status and to assess its diagnostic potential for identifying dysglycemia. Materials and methods. A case-control study was conducted with 120 participants divided into four groups: healthy controls, metabolic syndrome without diabetes, metabolic syndrome with prediabetes, and metabolic syndrome with type 2 diabetes mellitus. Anthropometric data and biochemical indices (fasting glucose, glycated hemoglobin, lipid profile, and HOMA-IR) were collected. Serum asprosin levels were quantified using enzyme-linked immunosorbent assay. Statistical analyses included Kruskal-Wallis tests, Spearman’s correlations, and ROC curve analyses. Results. Serum asprosin levels were significantly elevated in all metabolic syndrome cohorts compared to controls (p < 0.001). Asprosin levels correlated positively with body mass index, waist circumference, fasting glucose, HbA1c, HOMA-IR, and atherogenic lipids, and inversely correlated with high-density lipoprotein cholesterol. ROC analysis indicated strong diagnostic performance for metabolic syndrome in prediabetes (AUC = 0.863), metabolic syndrome in type 2 diabetes mellitus (AUC = 0.839), and isolated metabolic syndrome (AUC = 0.807). Conclusions. Elevated circulating asprosin levels are intrinsically linked to the progressive deterioration of glucose homeostasis and adverse lipid profiles, positioning it as a promising predictive indicator for cardiometabolic risk stratification and glycemic impairment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.